These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32797088)

  • 1. Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation.
    Kesselmeier M; Benda N; Scherag A
    PLoS One; 2020; 15(8):e0237441. PubMed ID: 32797088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods.
    Ouma LO; Grayling MJ; Zheng H; Wason J
    Pharm Stat; 2021 Nov; 20(6):990-1001. PubMed ID: 33759353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction.
    Habermehl C; Benner A; Kopp-Schneider A
    Biom J; 2018 Mar; 60(2):275-287. PubMed ID: 28762532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.
    Zheng H; Wason JMS
    Biostatistics; 2022 Jan; 23(1):120-135. PubMed ID: 32380518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian modelling strategies for borrowing of information in randomised basket trials.
    Ouma LO; Grayling MJ; Wason JMS; Zheng H
    J R Stat Soc Ser C Appl Stat; 2022 Nov; 71(5):2014-2037. PubMed ID: 36636028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of characteristics of women on attendance in blind and non-blind randomised trials: analysis of recruitment data from the EPHT Trial.
    Veerus P; Fischer K; Hemminki E; Hovi SL; Hakama M
    BMJ Open; 2016 Oct; 6(10):e011099. PubMed ID: 27797984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.
    Korn EL; Freidlin B
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal design for inference on the threshold of a biomarker.
    Baldi Antognini A; Frieri R; Rosenberger WF; Zagoraiou M
    Stat Methods Med Res; 2024 Feb; 33(2):321-343. PubMed ID: 38297878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of precision oncology basket and umbrella trials for clinicians.
    Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ
    CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethics and practice of Trials within Cohorts: An emerging pragmatic trial design.
    Kim SY; Flory J; Relton C
    Clin Trials; 2018 Feb; 15(1):9-16. PubMed ID: 29224380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allocation concealment: a methodological review.
    Clark L; Schmidt U; Tharmanathan P; Adamson J; Hewitt C; Torgerson D
    J Eval Clin Pract; 2013 Aug; 19(4):708-12. PubMed ID: 23648092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies.
    Zhang W; Zhang Z; Krushkal J; Liu A
    BMC Med Res Methodol; 2021 Mar; 21(1):55. PubMed ID: 33740890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methods for control allocation in multiple arm studies using response adaptive randomization.
    Viele K; Broglio K; McGlothlin A; Saville BR
    Clin Trials; 2020 Feb; 17(1):52-60. PubMed ID: 31630567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
    Chen YF; Yang Y; Hung HM; Wang SJ
    Contemp Clin Trials; 2011 Jul; 32(4):592-604. PubMed ID: 21540126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur.
    Newcombe RG
    Stat Med; 1988 Nov; 7(11):1179-86. PubMed ID: 3201044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of constrained randomization for the design and analysis of group-randomized trials with binary outcomes.
    Li F; Turner EL; Heagerty PJ; Murray DM; Vollmer WM; DeLong ER
    Stat Med; 2017 Oct; 36(24):3791-3806. PubMed ID: 28786223
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.